GE HealthCare's revenue has re-accelerated to 7.2% year-over-year growth in 2026Q3 on a base of $5.5B, and operating margin expanded from 13.1% to 14.6% over the recent quarters while SG&A held near $1.0 to $1.1B.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew from about $4.8B in 2024Q2 to $5.5B in 2026Q3 with growth rebounding to 7.2%, while operating margin improved to 14.6%, though gross margin volatility between 38.5% and 54.3% suggests timing-driven swings.
GE HealthCare Technologies Inc. presents a compelling investment case supported by a strengthening balance sheet and durable cash generation.
The company has significant valuation upside following its spinoff, with trailing and forward P/E ratios indicating potential for rerating.
GE HealthCare has received FDA clearance for Photonova Spectra, a photon-counting CT platform with advanced imaging and data processing capabilities, enabling U.S. commercial rollout.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | $1.34+11.7% vs $1.20 | $5.5B+3.0% vs $5.4B |
Q3 2026 Jul 29, 2026 | $1.13+8.7% vs $1.04 | $5.3B+0.6% vs $5.3B |
Q2 2026 Apr 29, 2026 | $0.99-4.8% vs $1.04 | $5.1B+1.8% vs $5.0B |
Q1 2026 Feb 4, 2026 | $1.44+2.9% vs $1.40 | $5.7B+1.5% vs $5.6B |
GEHC's Allia Celeo launch expands its interventional imaging portfolio with AI-powered precision, flexible workflows and predictive service capabilities.
GE HealthCare raises its 2026 earnings outlook on strong Q3 results, but tariff risks, fourth-quarter growth concerns and margin pressures remain in focus.
GE HealthCare (Nasdaq: GEHC) today announced two new AI-assisted capabilities for its Vscan Air⢠handheld ultrasound system: Lung Guidance and AutoAS.1 Design
GE HealthCare (Nasdaq: GEHC) today introduced Allia⢠Celeo,* a ceiling-mounted image guiding system, at the Transcatheter Cardiovascular Therapeutics (TCT) 20
Benchmark GEHC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for GE HealthCare Technologies Inc. (GEHC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $82.38 | $37.21B | 18.11 | 4.84% | 10.1% | 21.65% | 0.17% | |
| $325.78 | $124.89B | 38.78 | 11.16% | 13.78% | 15.61% | 1.03% | |
| $42.75 | $63.54B | 22.04 | 19.87% | 16.56% | 13.74% | — | |
| $102.14 | $58.81B | 55.81 | 11.55% | 15.43% | 9.66% | — | |
| $30.35 | $29.66B | 29.20 | -1.04% | 5.4% | 8.37% | 1.25% | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — |
GE HealthCare Technologies Inc. (GEHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
GE HealthCare Technologies Inc. (GEHC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Jul 29, 2026·SEC
Jul 29, 2026·SEC
Get notified when GEHC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GE HealthCare Technologies Inc. (GEHC) stock FAQ — growth, dividends, profitability & financials explained
GE HealthCare Technologies Inc. (GEHC) reported $20.63B in revenue in fiscal year 2025, which is also its trailing twelve months. That is 20% more than the $17.16B of fiscal year 2020.
GE HealthCare Technologies Inc. (GEHC) grew revenue by 4.8% in fiscal year 2025, compared with the prior fiscal year.
Yes. GE HealthCare Technologies Inc. (GEHC) earned $1.76B in net income over the trailing twelve months (a 8.5% net margin).
Yes. GE HealthCare Technologies Inc. (GEHC) pays a dividend that yields 0.17% at the current price, a small yield.
GE HealthCare Technologies Inc. (GEHC) had a return on equity (ROE) of 21.6% in fiscal year 2025. That is well above the market's typical 10-15%.
GE HealthCare Technologies Inc. (GEHC) generated $1.21B in free cash flow over the trailing twelve months.
